News Roundup | FDA Issues Warning About mRNA-based Vaccines: Higher Risk for Heart Inflammation

Join The Conversation! | https://trialsitenews.com/
FDA Issues Warning to Consuming Public About mRNA-based Vaccines: Higher Risk for Heart Inflammation:

As reported by a number of major media outlets recently, the U.S Food and Drug Administration (FDA) moved forward to include a warning concerning for the Moderna and Pfizer-BioNTech Covid-19 vaccines, regarding the suggested increased risks of myocarditis (or, inflammation of the heart muscle, and pericarditis (inflammation of the tissue surrounding the heart, following vaccination.
Article Link | https://trialsitenews.com/fda-to-issue-warning-to-consuming-public-about-mrna-based-vaccines-higher-risk-for-heart-inflammation/

Ivermectin Authorized in Indonesia as Pharma Issued License for Production to Battle COVID-19:
Indonesia’s now in the middle of its most severe wave of the COVID-19 pandemic. Now thanks in part to a wealthy entrepreneur presently serving as the Minister for State Owned Enterprises (SOE), the country’s national drug regulator authorized the use of ivermectin on an off-label basis targeting COVID-19. In 2020, the Indonesian government brought in a wealthy, dynamic, and aggressive businessman to shake up and turn around state-owned enterprises known as “SOE.” Now they’ve turned Erick Thohir loose on COVID-19, and there’s nothing but business. A pragmatic yet big thinker, the new SOE Minister of the Food and Drug Supervisory Agency, known for the acronym BPOM, issued a distribution permit for ivermectin, meaning the regulatory body for this Southeast Asian nation of 270 million, the worlds’ fourth most populous nation, has authorized the use of the generic, low-cost drug as a therapeutic for COVID-19. Based on the results of a study, this BPOM action led to a distribution license to PT Indofarma Tbk; and production now has commenced with plans for distribution of over 4 million units per month.
Article Link | https://trialsitenews.com/ivermectin-authorized-in-indonesia-as-pharma-issued-license-for-production-to-battle-covid-19/